What triggered the latest move in Ligand Pharmaceuticals stock

Ligand Pharmaceuticals (LGND) has come into focus after being dropped from several Russell value and small cap benchmarks shortly after completing a US$625 million zero coupon convertible bond offering due September 15, 2031.

Those index removals and the new convertible bond appear to be landing on a stock that already had strong momentum, with a 30 day share price return of 34.83% and a 1 year total shareholder return of 180.90% contributing to a multi year total shareholder return above 3x.

If Ligand Pharmaceuticals’ recent surge has you looking beyond a single stock, this is a good moment to widen your research using the 40 healthcare AI stocks.

Ligand Pharmaceuticals now combines a sizeable royalty portfolio, growing earnings and a sharp rerating after its index exits and convertible bond deal. The key tension is whether that stronger story is already fully reflected in the current price.

Most Popular Narrative: 15.1% Overvalued

At a last close of $319.55 versus a narrative fair value of $277.60, the current Ligand Pharmaceuticals share price sits above that widely followed model, which leans heavily on the earnings power of its royalty portfolio.

Strong revenue and earnings growth are expected as Ligand broadens its high margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long term cash flow predictability.

Want to see what is built into that cash flow story? The narrative leans on robust revenue growth, high margins and a premium earnings multiple. The exact mix of those levers might surprise you.

Result: Fair Value of $277.60 (OVERVALUED)

However, for Ligand Pharmaceuticals, pressure on drug pricing or setbacks across key royalties such as Filspari or Zelsuvmi could quickly challenge the current earnings story.

Another View: SWS DCF Model Backs A Different Fair Value For Ligand Pharmaceuticals

The analyst narrative frames Ligand Pharmaceuticals as 15.1% overvalued at $319.55 versus a $277.60 fair value, but the SWS DCF model points the other way, with a future cash flow value of $404.09, implying the stock trades at a discount. Which story you lean on depends on how much weight you give to long term cash flows versus earnings multiples.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ligand Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mixed picture around Ligand Pharmaceuticals, it makes sense to move quickly, compare both the upside and the concerns, and reach your own view by weighing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ligand Pharmaceuticals?

If the moves in Ligand Pharmaceuticals have sharpened your attention, do not stop here. Broaden your watchlist with other focused stock ideas that could suit your style.

• Scan for underappreciated opportunities by checking companies on the 44 high quality undervalued stocks that pair quality fundamentals with pricing that may not fully reflect them.
• Target consistency by reviewing the 7 dividend fortresses to see which companies combine income potential with an emphasis on durability.
• Prioritize resilience by using the 73 resilient stocks with low risk scores to focus on stocks assessed with steadier risk profiles and solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.